MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a period of improvement (relapsed) or that remains despite treatment (resistant). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and are made in a laboratory to recognize MUC1, a protein on the surface of tumor cells that plays a key role in tumor cell growth. These MUC1-activated T cells may help the body's immune system identify and kill MUC1 expressing ovarian

Trial Details

NCT ID

NCT06483048

Phase

PHASE1

Sponsor

Mayo Clinic

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

Autologous MUC1-activated T-cells
Bendamustine
Biospecimen Collection
Computed Tomography
Cyclophosphamide
Echocardiography

Locations (sample)

Scottsdale, Arizona, United States|33.50921,-111.89903

Key Eligibility Criteria

PRE-REGISTRATION: Age ≥ 18 years
PRE-REGISTRATION: Diagnosis or history of epithelial ovarian, fallopian tube, carcinosarcoma, or primary peritoneal cancer
PRE-REGISTRATION: Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria on study entry, which mu…
Skin lesions can be used if the area is ≥ 1cm in at least one diameter and measured with a ruler

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →